Stock-based compensation (Tables)
|
9 Months Ended |
Dec. 31, 2025 |
| Share-Based Payment Arrangement [Abstract] |
|
| Schedule of stock-based compensation expense |
Stock-based compensation expense was classified in the consolidated statements of operations as follows: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended December 31, | | Nine Months Ended December 31, | | 2025 | | 2024 | | 2025 | | 2024 | | Research and development | $ | 3,609 | | | $ | 4,573 | | | $ | 12,677 | | | $ | 13,927 | | | Selling, general and administrative | 3,438 | | | 4,066 | | | 11,470 | | | 12,837 | | | $ | 7,047 | | | $ | 8,639 | | | $ | 24,147 | | | $ | 26,764 | |
The following table summarizes stock-based compensation expense by award type for the three and nine months ended December 31, 2025 and 2024: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended December 31, | | Nine Months Ended December 31, | | 2025 | | 2024 | | 2025 | | 2024 | | Stock options | $ | 3,630 | | | $ | 4,839 | | | $ | 11,928 | | | $ | 15,466 | | Restricted and performance stock units | 3,417 | | | 3,800 | | | 12,219 | | | 11,298 | | | $ | 7,047 | | | $ | 8,639 | | | $ | 24,147 | | | $ | 26,764 | |
|
| Schedule of assumptions used to determine the grant-date fair value of stock options granted |
The following table presents, on a weighted-average basis, the assumptions that the Company used to determine the grant-date fair value of stock options granted to employees and directors: | | | | | | | | | | | | | | | | | | | | | | Three Months Ended December 31, | Nine Months Ended December 31, | | 2025 | | 2024 | 2025 | | 2024 | | Risk-free interest rate | 3.75 | % | | 4.10 | % | 3.97 | % | | 4.36 | % | | Expected term (in years) | 6.1 | | 6.1 | 6.0 | | 6.0 | | Expected volatility | 107.2 | % | | 76.5 | % | 76.9 | % | | 76.3 | % | | Expected dividend yield | 0 | % | | 0 | % | 0 | % | | 0 | % |
|
| Schedule of of stock option activity |
The following table summarizes the Company’s stock option activity: | | | | | | | | | | | | | | | | | | | | | | | | | Number of Shares | | Weighted Average Exercise Price | | Weighted Average Contractual Term (Years) | | Aggregate Intrinsic Value | | Outstanding as of March 31, 2025 | 10,214,878 | | | $ | 15.22 | | | 6.24 | | $ | 10,652 | | | Granted | 2,183,724 | | | $ | 8.42 | | | | | | | Exercised | (70,966) | | | $ | 4.08 | | | | | | | Cancelled | (399,666) | | | $ | 13.60 | | | | | | | Outstanding as of December 31, 2025 | 11,927,970 | | | $ | 14.10 | | | 5.83 | | $ | 12,758 | | | Options exercisable as of December 31, 2025 | 8,014,980 | | | $ | 16.09 | | | 4.48 | | $ | 8,281 | | | Options vested and expected to vest as of December 31, 2025 | 11,927,970 | | | $ | 14.10 | | | 5.83 | | $ | 12,758 | |
|
| Schedule of share-based payment arrangement, restricted stock and restricted stock unit, activity |
A summary of the changes in the Company's RSUs and PSUs during the nine months ended December 31, 2025 is as follows: | | | | | | | | | | | | | Number of Restricted Shares | | Weighted Average Grant Date Fair Value | | Outstanding as of March 31, 2025 | 3,611,774 | | | 12.40 | | | Granted | 3,464,911 | | | 8.82 | | | Vested | (898,310) | | | 16.33 | | | Cancelled | (515,352) | | | 10.57 | | | Outstanding as of December 31, 2025 | 5,663,023 | | | $ | 9.76 | |
|